Cargando…

Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors

Glutathione S‐transferase pi (GSTP1), a phase II detoxification enzyme, is known to be overexpressed and mediates chemotherapeutic resistance in lung cancer. However, whether GSTP1 supports cancer stem cells (CSCs) and the underlying mechanisms in lung adenocarcinoma (LUAD) remain largely unknown. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Si‐Qi, Chen, Jun‐Jiang, Jiang, Yuchen, Lei, Zi‐Ning, Ruan, Ye Chun, Pan, Yihang, Yam, Judy Wai Ping, Wong, Maria Pik, Xiao, Zhi‐Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982593/ https://www.ncbi.nlm.nih.gov/pubmed/36709476 http://dx.doi.org/10.1002/advs.202205262

Ejemplares similares

CAMK2A supported tumor initiating cells of lung adenocarcinoma by upregulating SOX2 through EZH2 phosphorylation
por: Wang, Si-Qi, et al.
Publicado: (2020)

Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor
por: Yang, Yuqi, et al.
Publicado: (2020)

Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor
por: Zhuang, Hongqing, et al.
Publicado: (2019)

Prohibitin: a potential therapeutic target in tyrosine kinase signaling
por: Ande, Sudharsana Rao, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
por: Cheng, Mengfei, et al.
Publicado: (2021)

Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes
por: Althubiti, Mohammad
Publicado: (2022)

GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States
por: Vidal, Igor, et al.
Publicado: (2021)

Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation
por: Mariotti, Evan T, et al.
Publicado: (2014)

Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer
por: Zou, Hailin, et al.
Publicado: (2023)

Prognostic significance of GSTP1 in patients with triple negative breast cancer
por: Chen, Guanglei, et al.
Publicado: (2017)

Insights into the Distinguishing Stress-induced Cytotoxicity of Chiral Gold Nanoclusters and the Relationship with GSTP1
por: Zhang, Chunlei, et al.
Publicado: (2015)

CLDN6 promotes chemoresistance through GSTP1 in human breast cancer
por: Yang, Minlan, et al.
Publicado: (2017)

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?
por: Marcq, Marie, et al.
Publicado: (2014)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer
por: ZHANG, WEIJIE, et al.
Publicado: (2015)

Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation
por: Leung, Elaine Lai-Han, et al.
Publicado: (2016)

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
por: Cazes, Alex, et al.
Publicado: (2022)

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions
por: Mendes‐Bastos, Pedro, et al.
Publicado: (2022)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
por: Brindel, Aurélien, et al.
Publicado: (2020)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling
por: KOU, XIANJUAN, et al.
Publicado: (2013)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016)

Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer
por: Jerin, Samanta, et al.
Publicado: (2023)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

Frequency of NAT2 and GSTP1 polymorphisms in the Kazakh population
por: Iskakova, Aisha, et al.
Publicado: (2014)

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
por: Jiang, Zhansheng, et al.
Publicado: (2018)

Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report
por: ZHANG, NA, et al.
Publicado: (2014)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma
por: Hudson, C D, et al.
Publicado: (2014)

Downregulation of VPS13C promotes cisplatin resistance in cervical cancer by upregulating GSTP1
por: Tan, Xiangyu, et al.
Publicado: (2023)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
por: Roesler, Rafael, et al.
Publicado: (2021)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sudhesh Dev, Sareshma, et al.
Publicado: (2021)

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
por: Nakade, Issei, et al.
Publicado: (2023)

High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma
por: Liu, Xiaojia, et al.
Publicado: (2017)

Establishment of a 4-miRNA Prognostic Model for Risk Stratification of Patients With Pancreatic Adenocarcinoma
por: Gong, Xun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1jt9v0421dc6e88p41fpq0rhqq